SCHEMBL25348490

SCHEMBL25348490

Fc1cc(-c2nnc(C(F)F)o2)ccc1Cn1cc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nn1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 1/20 0.44
▸ HSP90AB1 P08238 1/20 0.44
▸ HDAC6 Q9UBN7 5/20 0.42
▸ ROCK2 O75116 1/20 0.40
▸ PRKACA P17612 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CLK2 P49760 1/20 0.40
▸ GSK3A P49840 1/20 0.40
▸ CSNK1G2 P78368 1/20 0.40
▸ ROCK1 Q13464 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ HDAC1 Q13547 9/20 0.40
▸ GPR55 Q9Y2T6 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ TEK Q02763 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25350410 0.87 HDAC6 (0.45) HDAC6ROCK2HDAC1
SCHEMBL25992736 0.86 HDAC6 (0.43) HDAC6HDAC1
SCHEMBL24215834 0.86 HDAC1 (0.48) HDAC6ROCK2HDAC1
SCHEMBL30409440 0.86 HDAC1 (0.48) HDAC6ROCK2HDAC1
SCHEMBL25354191 0.86 HDAC6 (0.55) HSP90AA1HSP90AB1HDAC6GPR55KDR
SCHEMBL25351646 0.85 DPP4 (0.48) HDAC6ROCK2PRKACARPS6KB1MAPK1
SCHEMBL25352081 0.83 HDAC6 (0.49) HDAC6HDAC1
SCHEMBL25351050 0.82 HDAC6 (0.44) HDAC6ROCK2HDAC1
SCHEMBL25351906 0.82 HDAC6 (0.44) HDAC6HDAC1
SCHEMBL24215788 0.82 HDAC1 (0.42) HDAC6ROCK2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116157398-B Oxadiazole-based selective histone deacetylase 6 inhibitors 意大发马克股份公司 2025-03-11 — — CN claimed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257372-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC3 HSP90AA1 153/4885HSP90AB1 96/4885HDAC6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback